Apogee Enterprises Inc. (APOG)
Apogee Q1 Earnings Beat Estimates on Pricing, Productivity Gains
APOG beat Q1 earnings and revenue estimates as pricing, productivity gains and Project Fortify savings help offset lower volume and higher costs.
APOG Q1 Earnings Call Keeps Focus on Kalwall, Guidance
Apogee keeps fiscal 2027 guidance intact as pricing, Fortify savings and the pending Kalwall deal frame its response to soft demand.
Apogee Enterprises: Hedge Against AI Portfolio Risk
Apogee Enterprises delivered a double-beat quarter and raised its FY2027 outlook, sparking a 15% stock surge. I initiate APOG with a buy rating, citing its turnaround potential and appeal as an anti-AI, diversification candidate. The Kalwall acquisition adds an $85 million revenue run rate, complementing cost-cutting and buyback strategies.
Apogee Enterprises, Inc. (APOG) Q1 2027 Earnings Call Transcript
Apogee Enterprises, Inc. (APOG) Q1 2027 Earnings Call Transcript
Apogee Enterprises (APOG) Beats Q1 Earnings and Revenue Estimates
Apogee Enterprises (APOG) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.56 per share a year ago.
New Strong Sell Stocks for June 2nd
APOG, BIDU and EGO have been added to the Zacks Rank #5 (Strong Sell) List on June 2nd, 2026.
Apogee Expands Architectural Glass Segment With Kalwall Buyout
APOG's $115M Kalwall buyout expands its architectural glass portfolio with high-performance daylighting solutions.
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program
Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic royalty financing with as much as $500 million in senior corporate debt, giving the immunology developer runway to advance Phase 3 development and potential commercialization of its lead candidate zumilokibart. The financing structure pairs royalty-based capital tied to future product revenue with senior debt capacity.
Apogee Enterprises, Inc. (APOG) Q4 2026 Earnings Call Transcript
Apogee Enterprises, Inc. (APOG) Q4 2026 Earnings Call Transcript
Apogee Enterprises (APOG) Q4 Earnings and Revenues Surpass Estimates
Apogee Enterprises (APOG) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.89 per share a year ago.
Apogee Enterprises (APOG) Reports Next Week: What to Know Ahead of the Release
Apogee Enterprises (APOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apogee Enterprises: The Discount Is What Matters, Especially With Cost-Cutting
Apogee Enterprises remains a "Buy" despite ongoing margin compression and recent downward revisions in profitability guidance. APOG's valuation is highly attractive, trading at mid-single-digit multiples and significantly cheaper than peers, suggesting substantial upside potential. Management has increased cost-saving targets under Project Fortify to $25–$26 million pre-tax, partially offsetting tariff impacts and segment-specific profit declines.
